iTrack™ is the only illuminated, micron-scale microcatheter designed to viscodilate Schlemm’s canal during MIGS with ABiC™. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation.

ABiC WITH iTRACK

SCHEDULE A DEMO

Performed as a standalone procedure or as an adjunct to cataract surgery, ABiC is a new MIGS procedure that can comprehensively restore the natural outflow pathway in glaucoma patients.

Introducing a new comprenhensive MIGS

LEARN MORE

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

LEARN MORE

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

LEARN MORE

2RT® is a nanosecond laser therapy that stimulates a natural, biological healing response in the eye to treat degenerative retinal disease, including AMD.

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For more than 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 30,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

6 May 2015

Ellex lifts Global Market Share

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical technologies for the diagnosis and treatment of eye disease, today announced the results of an independent assessment of the global ophthalmic laser industry prepared by the respected industry consultant Market Scope®, LLC. The assessment was released in April 2015 in the report entitled “2015 Comprehensive Report on the Global Ophthalmic Laser Market”.

The assessment reported that the global ophthalmic laser market is currently valued at US$412million per annum. The assessment forecast global demand for ophthalmic lasers to grow at a compounded rate of 4.5% per annum from 2015 to 2020, which represents an increase over the previous forecast growth rate of 3.3% per annum reported 12 months earlier.

The assessment also reported that Ellex materially increased its global market share during the 12-month period from 12.7% to 14.2%. Ellex is now only 0.3 percentage points of market share behind the market leader compared with 4.1 percentage points behind 12 months earlier.

“We are pleased to have our position as a leading market participant independently verified. The positive momentum of our business is demonstrated by our growing share of a growing global market. It is also encouraging to note that the market for our products and services continues to grow at a strong rate, offering significant opportunity for the continued expansion of the Ellex business.” commented Ellex CEO, Tom Spurling.

The assessment also detailed the Company’s improved result in the sub-market of glaucoma treatment lasers, with Ellex now ranked first in the world at 50%, up from 41% 12 months earlier. The Company also experienced growth in market share for photodisruptor YAG lasers, growing from 15.3% to 18.7% market share, which also ranks Ellex first in the world.

“Our world-leading Tango™ SLT laser and Ultra Q Reflex™ YAG laser have been key drivers for our business over the past 12 months. This demonstrates that Ellex’s investment in leading edge technology can successfully translate into increased sales and market share and we intend to continue to build our pipeline of product innovation in the ophthalmic space.” added Mr. Spurling.

The Ultra Q Reflex™ laser is a proprietary photodisruptor YAG laser for the treatment of vitreous floaters. Featured at the recent American Society Cataract and Refractive Surgeons (ASCRS) meeting in San Diego, it is the only commercially available laser for the treatment of floaters.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the development of medical technologies for the diagnosis and treatment of eye disease. With more than 20,000 systems delivered to market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, France, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products. On 31 December 2013 Ellex acquired the Canaloplasty microcatheter-based glaucoma surgical treatment from iScience Interventional, Inc.

For additional information about Ellex and its products, please visit www.ellex.com